SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort study

- 4 Mohamed Hadi Mohamed Abdelhamid^{a,b,}, Iman A. Almsellati^c, Badereddin B Annajar^d,
- 5 Alaa .H Abdelhamid^e, Hafsa .A Alemam^f, Mohammed Etikar^a.
- ^a National Center of Disease Control (NCDC), Tripoli Libya.
- 7 b Department of Cell Biology and Tissue Culture, Biotechnology Research Center
- 8 (BTRC), Tripoli Libya.
- ⁹ Primary Health Care, National Center of Disease Control (NCDC), Tripoli Libya.
- d Department of Public Health, Faculty of Medical Technology, University of Tripoli, Tripoli
- 11 13662, Libya.

1 2

3

14

15

16

17

18

19

20

21

22

23

24

25

26

27

- e Department of Cardiology, Tripoli University Hospital, Tripoli, Libya.
- ^f Department of Environment, Biotechnology Research Center (BTRC), Tripoli Libya.

* Corresponding author: Mohamed Hadi Mohamed Abdelhamid, National Center of Disease Control (NCDC), Department of Cell Biology and Tissue Culture, Biotechnology Research Center (BTRC), Tripoli - Libya; Email: Mohamed.abdelhamid@btc.org.ly; Moh9363@gmail.com Phone N: 00 218 916030276. Running title: Breakthrough vaccine infection after one dose in Libya. **Funding** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Abstract:

SARS-CoV-2 infection is widely spread over people, from youth to the elderly. Vaccination against SARS-CoV-2 is an important preventive measurement to help end the SARS-CoV-2 pandemic. From 30 April to 15 July, we collected the number of people infected with SARS-COV-2 and the mortality rate from daily reports issued by the National Center for Disease Control of Libya (NCDC). Approximately 445000 doses have been administered in Libya since 10 April, and 5 thousand doses are now being administered during this period on a daily basis. To estimate the rate of breakthrough vaccine infection of the SARS-COV-2 in Libya. We found that one dose of the three different types of vaccines had decreased the virus transmission across people and mortality rate until 10 weeks after the first dose. This study highlights the dramatic success of the early months of the nation's coronavirus vaccines rollout.

Key Words: SARS-COV-2; Breakthrough vaccines infection; One dose SARS-COV-2 vaccine; Libya

Introduction:

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

SARS-CoV-2 infection is widely spread over people, from youth to the elderly. Mass vaccination operations to prevent coronavirus disease 2019 (Covid-19) are ensuing in 207 countries; 32% of the world population has received at least one dose of a SARS-CoV-2 vaccine, and 24% is fully vaccinated [1]. Approximately 4,84 billion doses have been administered worldwide, and 34,86 million are now administered daily [1,2]. Interestingly, SARS-CoV-2 several studies have found that most hospitalizations and deaths due to SARS-CoV-2 infection were among immunocompromised individuals, persons with co-morbidities, elderly and / or unvaccinated people [3–5]. Furthermore, previous studies showed that the vaccines reduce the risk of SARS-CoV-2 infection, especially illness severity, among partially vaccinated people [6–9] (Table 1). Libya's National Center for Disease Control (NCDC) reported that the first case of SARS-CoV-2 was identified in Libya on 24 Mars 2020 [10–12]. In addition, as reported by the World Health Organization (WHO), many countries are not very well-prepared to fight the pandemic such as (Libya, Iraq, and Yemen) these countries are more vulnerable to the impact of this pandemic [13]. Nevertheless, In Libya, the national immunization program launched a long-delayed SARS-CoV-2 vaccination program on 10 April 2021, through 400 immunization centers distributor in all cities of the country [12]. Currently, most cases of SARS-CoV-2 effects people who have not been fully vaccinated. Over the world, many hospitals have recorded cases of SARS-CoV-2 infection in patients after being fully vaccinated, this situation is called a vaccine

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

breakthrough cases [2,14]. Although SARS-CoV-2 vaccines right now appear to be very effective against the disease severity and deaths, no vaccine is perfect [15]. Furthermore, two studies in Scotland and England confirm high protection rates (80%-91%) after the first dose of Pfizer or Oxford/AstraZeneca vaccines [3,4]. Previous studies have found that a single dose of the Sputnik V vaccine may be enough to elicit a strong antibody response against SARS-CoV-2 [16,17]. However, In the United States, the U.S. Center for Disease Control and Prevention (CDC) reported a total of 10,262 SARS-CoV-2 vaccine breakthrough infections from 46 U.S. states and territories as of April 30, 2021[18]. A recent study reported that the effectiveness of the vaccines against infections had decreased from 91.7% to 79.8% between 3 May and 25 July in New York [19]. Additionally, a study published by National Healthcare Safety Network (NHSN) found that the two mRNA (nucleoside-modified) vaccines (Pfizer-BioNTech and Moderna) were effective by 74.7% in nursing home residents between March and May, however, the protection has declined to 53.1% between June and July[20]. Investigating the trend of SARS-CoV-2 infection severity, hospitalizations rate, and deaths among persons who got the first dose of the SARS-CoV-2 vaccine are urgently needed to support decision-making logistics such as cold chains, vaccination schedules, and follow-up.

Material and methods

We collected SARS-CoV-2 infection and mortality rate data by the NCDC daily reports from 30 April 2021 until 15 July 2021. The study includes all patients who were admitted to hospitals with confirmed SARS-CoV-2 by repeat reverse-transcriptase–polymerase-chain-reaction assays (RT-PCR). The data were collected from the medical record of the patients by intensive care physicians and healthcare centers staff working in 34 healthcare centers and hospitals from different cities. Inclusion criteria were all vaccinated and unvaccinated cases admitted to the healthcare centers during this period. Concurrently, we tracked the number of people who received the first dose of the SARS-CoV-2 vaccine since 10 April 2021.

Ethics statement

The study was approved by the Ethics Committee (National committee for Biosafety and Bioethics at Biotechnology Research Center, Tripoli - Libya, Nº: BTRC- 2021).

First Dose of COVID-19 Vaccines:

As the emergence of the new variant strains of SARS-CoV-2 B.1.617.2 (Delta) in the world in December 2020, they have led to a rapid increase in the circulation of the virus and a rising demands for vaccines.

UNICEF, through COVID-19 Vaccines Global Access (COVAX), supported the Libyan government by delivering 57,600 doses at 8 April 2021[21]. Also, as an intranational gift the Libya government received an around 200,000 doses of (Sputnik V) vaccines, and 150,000 doses of Sinovac vaccine on April 2021[12]. Thus, a countrywide mass vaccination campaign with the use of three different authorized vaccines

(Oxford/AstraZeneca, Sinovac, Sputnik V) was conducted in Libya starting from 10 April, 2021[22]. Nearly 5000 doses were administered daily through 400 immunization centers in all cities of the country. So far, about 445,000 people have received the first dose of vaccines that provided by the national immunization program. Priority was given to frontline healthcare and hospitals workers, adults over 60, and patients with chronic underlying health conditions in all regions of the country. Hance, 110,000 doses of Sinovac, 175,000 doses of Oxford/AstraZeneca, and 160,000 doses of Sputnik V were administered. The National Center for Disease Control (NCDC) has recommended that the Oxford/AstraZeneca vaccine to be used for people aged over 55 years old. The other vaccines (Sinovac and Sputnik V) to be used for people who is 16 years old or more. Moreover, due to delays in providing vaccines throughout COVAX and countries who are producing the vaccines, the NCDC announced a deviation from the recommended protocol for the SARS-CoV-2 vaccines, prolonging the interval between doses from 2 to 4 months. This procedure had two advantages: The first, a longer gap between doses may improve the long-term immune response, as demonstrated by AstraZeneca's vaccine[5]. Secondly, a larger number of elderly and people with chronic diseases will be vaccinate.

Hospital Admissions after one dose of vaccines

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

As of 15 July 2021, approximately 445000 persons in Libya had been received the first dose of the SARS-CoV-2 vaccines.

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

According to the NCDC data from 30 April 2021 (W1) to 15 July 2021 (W22), the total number of patients who have a confirmed SARS-CoV-2 infection is 39996. 3179 out of the total (7.9%) were admitted to healthcare centers, and among those 226 patients (7.10%) died during this period. At the same time, A total of 43 SARS-CoV-2 vaccine breakthrough infections (i.e. One dose obtained from the vaccine) were reported from 18 healthcare centers and hospitals as of 30 April 2021. Among these cases, 8 patients died. Patients in healthcare seem to be moving towards an average age of around 55-87 years old (Table 2). Notably, 23 patients who were admitted to healthcare centers are vaccinated with the CoronaVac (Sinovac) vaccine. 14 patients received the Oxford/AstraZeneca. While only two patients had the Sputnik V vaccine. Of 445000 people who had taken the first dose of the vaccines, the percentage of patients who had been admitted to the healthcare centers, and died is very low (0.009, 0.001%) respectively. Since July, the NCDC has reported initial evidence that people being infected with the Delta variant. Where the numbers testing positive increased five-fold, from 1600 the previous week to 15000 cases. It recorded its highest number of cases on 12 July (W20). However, the number of patients' deaths remains lower compared to W11 (17-26 patients per day) (Fig.1). In this period (W20), with delays in travel restrictions, there has been a significant increase in the number of people confirmed with SARS-CoV-2. Particularly in the western cities such as (Zawiya, Tripoli, Shakshok, Zliten, and Misrata), due to proximity to the

Tunisian borders, which was recording the peak of infection rates in Africa and in the world with Delta variant (Fig 2).

Limitations of study

The results in this study are subject to two limitations, the first one, that the number of reported SARS-CoV-2 vaccine breakthrough cases is substantially lower than that of all SARS-CoV-2 infections among one dose vaccinated persons. However, many people with vaccine breakthrough infections, especially those who are asymptomatic or who experience mild illness, might not seek testing. The second, SARS-CoV-2 sequence data are available for only a small proportion of the reported cases.

Conclusion

In the present study, one dose of the three different types of vaccines had showed a decreasing in infection and mortality rate. The results were very encouraging. However, all these results were before the delta variant entered Libya. So as a recommendation, the department of health and NCDC must focus and make all possible efforts to get as many people vaccinated within a short period of time to prevent the development of new virus variants.

Acknowledgements

The authors wish to thank all doctors in healthcare centers and hospitals who were involved in this study, and Hamza El-thelb for editing the text.

Conflicts of interest: The authors have declared that no competing interests exist.

Contributors: (I)Manuscript writing: All authors; (II) Final approval of manuscript: All authors.

Reference

227

228 1. Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald DB and MR. 229 Coronavirus Pandemic (COVID-19). OurWorldInData.org. 2021. Available: 230 https://ourworldindata.org/covid-vaccinations#citation 231 Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. 2. 232 233 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021; 1–11. doi:10.1056/nejmoa2107715 234 Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early 235 3. effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and 236 ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations 237 238 and mortality in older adults in England. medRxiv. 2021; 2021.03.01.21252652. Available: https://doi.org/10.1101/2021.03.01.21252652 239 Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim 240 4. 241 findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 242 243 2021;397: 1646–1657. doi:10.1016/S0140-6736(21)00677-2 5. lacobucci G, Mahase E. Covid-19 vaccination: What's the evidence for extending 244 the dosing interval? BMJ. 2021;372: n18. doi:10.1136/bmj.n18 245 Swan DA, Bracis C, Janes H, Moore M, Matrajt L, Reeves DB, et al. COVID-19 246 6. 247 vaccines that reduce symptoms but do not block infection need higher coverage 248 and faster rollout to achieve population impact. Sci Rep. 2021;11: 1–9.

- doi:10.1038/s41598-021-94719-y
- 7. Mallapaty BS. COVID VACCINES SLASH VIRAL SPREAD BUT.
- 8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
- 252 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384: 403-
- 416. doi:10.1056/nejmoa2035389
- 9. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of
- Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J
- 256 Med. 2021;385: 759–760. doi:10.1056/nejmc2107717
- 10. Bredan A, Bakoush O. COVID-19 epidemic in Libya. Libyan J Med. 2021;16.
- 258 doi:10.1080/19932820.2021.1871798
- 11. Rayes AA, Annajar BB, Dayhum AS, Eldaghayes IM. Why there were few cases
- of coronavirus disease 2019 in Libya during the first two months of the pandemic?
- 261 Int J One Heal. 2020;6: 160–164. doi:10.14202/IJOH.2020.160-164
- 12. Mahmoud AS, Dayhum AS, Rayes AA, Annajar BB, Eldaghayes IM. Exploiting
- epidemiological data to understand the epidemiology and factors that influence
- 264 COVID-19 pandemic in Libya. World J Virol. 2021;10: 156–167.
- 265 doi:10.5501/wjv.v10.i4.156
- 13. Gasibat Q, Raba AA, Abobaker A. COVID-19 in Libya, fewer cases so far. Any
- speculations? Disaster Med Public Health Prep. 2020; 2020–2021.
- 268 doi:10.1017/dmp.2020.177
- 14. Sankary KM, Sippel JL, Eberhart AC, Burns SP. Breakthrough cases of COVID-

19 in vaccinated United States Veterans with spinal cord injuries and disorders. 270 Spinal Cord. 2021; 1–2. doi:10.1038/s41393-021-00690-w 271 272 15. Dye C, Mills MC. COVID-19 vaccination passports. Science (80-). 2021;371. doi:10.1126/science.abi5245 273 16. Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, 274 Mazzitelli I, et al. Sputnik V vaccine elicits seroconversion and neutralizing 275 capacity to SARS-CoV-2 after a single dose. Cell Reports Med. 2021;2. 276 277 doi:10.1016/j.xcrm.2021.100359 17. Claro F, Silva D, Rodriguez M, Rangel R, de Waard JH. IgG Antibody response to 278 the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals might need 279 just one vaccine dose. Int J Infect Dis. 2021; 0-21. doi:10.1016/j.ijid.2021.07.070 280 CDC. COVID-19 Vaccine Breakthrough Infections Reported to CDC —. MMWR 281 18. Morb Mortal Wkly Rep. 2021;70: 792–793. 282 Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D. New COVID-283 19. 19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York 284 , May 3 – July 25, 2021. 2021;70. 285 Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H. Effectiveness of 20. 286 Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection 287 Among Nursing Home Residents Before and During Widespread Circulation of 288 the SARS-CoV-2 B . 1 . 617 . 2 (Delta) Variant — National Healthcare Safety

Network, March. 2021;70: 1163-1166.

289

Situation H, No R, Status F, Appeal U. Libya Country Office. 2021; 1-10. 21. NDCD. weekly updet of COVID-19 Libya. In: NCDC Libya [Internet]. 2021 pp. 1-22. 5. Available: https://ncdc.org.ly/Ar/

310 Table and Figure legend

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

Table 1 The efficacy of the vaccines against symptomatic, severe, and hospitalization SARS-CoV-2 infection. Table 2 Numbers of patients who were admitted to healthcare centers or hospitals after received one dose of vaccine in Libya. N: Number DM: Diabetic HT: Hypertension CoronaVac: Sinovac Astra: Oxford/AstraZeneca SputV: Sputnik v(-) = Data notavailable. Figure 1 Number of patients confirmed SARS-COV-2 Infection from February to 15 July in Libya. Green ring: start to vaccines program Red ring: first cases with Delta variant. Figure 2 The geographic distribution of SARS-COV-2 infection in Libya.

Table 1. shows the efficacy of the vaccines against symptomatic, severe, and hospitalization SARS-CoV-2 infection.

Vaccines	SARS-CoV-2 infection	vaccines against symptoms SARS-CoV-2 after receiving the first dose	Against hospitalization after receiving the first dose
AstraZeneca	67 %	68.7%	76%
Sputnik-V	80%	81%	87%
CoronaVac	49.6%	70%	99.2%

Table 2. Numbers of patients who were admitted to healthcare centers or hospitals after received one dose of vaccine in Libya

348

N	Healthcare center	N of patient (Type of vaccines)	N of died (Type of vaccine)	
1	Derna	2 (CoronaVAC)	1 (Astra)	
		1 (Astra)		
2	Marj	2 (CoronaVac)	0	
3	Bayda	1 (CoronaVac)	0	
4	Sabha	1 (Astra)	1 (Astra)	
5	Tripoli1 —	1 (Astra)	1 (CoronaVac)	
		1 (CoronaVac)		
		1 (Sput V)		
6	Tripoli 2	-	-	
7	Zliten	3 (Astra)	0	
8	Zawiya	-	-	
9	Misrata	-	0	
10	Zuwara	2 (CoronaVac)	1 (CoronaVac)	
		1 (Astra)		
11	Tegy	1 (Astra)	0	
12	Tobruq	2 (CoronaVac)	1 (Corona Vac)	
13	Ghadames —	2 (CoronaVac)	– 0	
		1 (Astra)		
14	Benghazi	2 (Astra)	0	
15	Shakshok	2 (CoronaVac)	1 (CoronaVac)	
16	Msallata	3 (CoronaVac)	1 (CoronaVac)	
17	Khoms1 —	1 (CoronaVac)		
		1 (Astra)		
18	Khoms2	1 (Sput V)		
		3 (CoronaVac)	1 (CoronaVac)	
		2 (Astra)		
		Total N of patient = 43	Total N of patient Died = 8	

Fig 1. Number of patients who confirmed SARS-COV-2 Infection Death/week 1892 1720 1859 1627 1695 W8 W9 W10 W11 W12 W1 W2 W3 W6 W7 Feb Mar Apr May Jun Jul Period Of Study

